Eiger BioPharmaceuticals, Inc.
EIGR
Hisse Senetlerindeki Sıralama
#36458
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Hisse Fiyatı
$1.73
Son senkronizasyon: 2025-06-17
Piyasa Değeri
$2.55M
Değişim (1 gün)
-0.29%
Değişim (1 yıl)
-79.71%
Ülke
US
Ticaret Eiger BioPharmaceuticals, Inc. (EIGR)
Kategori
Healthcare
Eiger BioPharmaceuticals, Inc. (EIGR) için kazanç
Dec 2023 itibarıyla kazanç TTM: $-74.96M
Eiger BioPharmaceuticals, Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı $-74.96M'dir. 2022 yılında şirket $-96.75M kazanç elde etti, bu 2021 yılındaki $-33.85M kazanca göre önceki yıla göre azalma. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Eiger BioPharmaceuticals, Inc. için kazanç geçmişi 2016 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $-74.96M | 0.00% |
| 2023 | $-74.96M | -22.53% |
| 2022 | $-96.75M | 185.80% |
| 2021 | $-33.85M | -47.96% |
| 2020 | $-65.05M | -7.40% |
| 2019 | $-70.25M | 34.09% |
| 2018 | $-52.39M | 23.42% |
| 2017 | $-42.45M | -9.85% |
| 2016 | $-47.09M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $5.27B | -7,137.23% |
US
|
|
| $-3.09B | 4,018.36% |
US
|
|
| $-4.02B | 5,258.00% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -2,702.36% |
NL
|
